Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database.

Jaykaran Charan Siddhartha DuttaRimplejeet KaurPankaj BhardwajPraveen SharmaSneha AmbwaniIffat JahanAbdullahi Rabiu AbubakarMd Salequl Islam Timothy Craig Hardcastle Nor Azlina A RahmanHalyna LugovaMainul Haque

Published in: Expert opinion on drug safety (2021)

Neutropenia, superinfections, reactivation of latent infections, hepatitis, and cardiac abnormalities were common ADEs observed that necessitate proper monitoring and reporting.

Keyphrases

adverse drug
coronavirus disease
sars cov
rheumatoid arthritis
electronic health record
left ventricular
juvenile idiopathic arthritis
emergency department
rheumatoid arthritis patients
drug induced
chemotherapy induced
respiratory syndrome coronavirus
heart failure
systemic lupus erythematosus